Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Microneedling for hair restoration involves daily use of a 0.3 mm device and weekly use of a 0.5 mm device. Combining microneedling with Minoxidil can enhance hair growth.

Microneedling aftercare involves using saline water instead of sea water, and avoiding hyaluronic acid due to its potential pro-inflammatory effects. Users suggest using jojoba oil as a carrier for essential oils like rosemary and lavender, and combining microneedling with minoxidil for better hair regrowth results.

Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.

Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.

An 18-year-old with early hair loss is advised to consider minoxidil and finasteride, with a doctor's consultation recommended. Alternatives like a hair system or shaving are suggested due to potential medication side effects and lifelong commitment.

Early hair loss causes emotional distress, and common coping strategies like fitness and fashion are inadequate. Treatments like finasteride, minoxidil, dutasteride, hair systems, and scalp micropigmentation were tried but were unsatisfactory.

Significant hair growth was achieved using Minoxidil 5% and dermarolling twice a week, with suggestions to add finasteride for maintenance. There is debate on when to apply Minoxidil after dermarolling to avoid irritation.

Finasteride and dutasteride may increase estrogen levels, leading to water retention and a fuller face. Users discuss managing these effects with lifestyle changes and supplements like zinc and DIM.

Thinning scissors can worsen the appearance of already thin hair. Some recommend being clear with barbers and using Minoxidil for hair loss.

Cannabis and THC may have mixed effects on hair, with some studies suggesting potential negative impacts on hair growth in isolated hair follicles, but these results are hard to apply to living humans. Treatments like minoxidil and finasteride are commonly used for hair loss, and the effects of cannabis might be neutral or vary based on individual factors.

Finasteride can aid hair regrowth but may cause side effects like depression and sexual dysfunction. Users discuss experiences with finasteride, minoxidil, and RU58841, highlighting varied responses and the importance of informed treatment choices.

The user is trying to maximize minoxidil's effectiveness by applying it for only one hour to avoid spreading it to furniture and pets, especially cats. They experience side effects when combining minoxidil with dermarolling and are considering alternatives like oral minoxidil or microneedling.

Hair loss treatments discussed include dermarolling, minoxidil, finasteride, and RU58841. Some users find dermarolling sad, while others mention the complexity of biological systems and limited research funding for hair loss.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

The conversation is about baricitinib, a medicine that can help with hair loss, and why it isn't more popular or widely discussed. No specific experiences with the treatment were shared.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Elevated bile acids can inhibit the enzyme AKR1C2, leading to increased DHT levels, which may accelerate hair loss in those predisposed to androgenetic alopecia. Treatments mentioned include topical minoxidil and finasteride.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

Breezula's development has stalled, leaving users disappointed. The conversation includes skepticism about its approval and effectiveness.

Breezula is discussed as a potential topical anti-androgen treatment for hair loss, with mixed opinions on its effectiveness and side effects compared to other treatments like finasteride, minoxidil, and RU58841. Some users express skepticism about its long-term efficacy and potential side effects, while others are hopeful for its approval and use in combination with existing treatments.

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.